# Supplementary Materials: Effect of Flavonoids on Oxidative Stress and Inflammation in Adults at Risk of Cardiovascular Disease: A Systematic Review

## Jenni Suen, Jolene Thomas, Amelia Kranz, Simon Vun and Michelle Miller

In reference to Section 2.2 Search Strategy (page 3 of the manuscript), the following search strategies were applied to each database:

#### Medline

1 *Polyphenols 1238 2 Limit 1 to (English language and humans) 594 Polyphenol.mp. (mp = title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier)  4 Limit 3 to (English language and humans) 2215 Flavonoid.mp (mp = title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier)  5 heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier)  6 Limit 5 to (English language and humans) 3212  * flavonoids/ or * anthocyanism/ or * benzoflavones/ or * flavonolis/ or * catechin/ or * chalcones/ or * flavanones/ or * flavonolignans/ or * flavonols/ or * 35,617  isoflavones/ or * proanthocyanidins/  8 Limit 7 to (English language and humans) 12,245  9 * Oxidative Stress/ 37,608  10 Limit 9 to (English language and humans) 17,936  11 * Inflammation/ 40,537  12 Limit 11 to (English language and humans) 23,251  Oxidative stress.mp (mp = title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, are disease supplementary concept word, unique identifier)  14 Limit 13 to (English language and humans) 56,835  Inflammat *.mp (mp = title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier)  16 Limit 14 to (English language and humans) 393,710  17 * Adult/ (English language and humans) 44,43,010  supplementary concept word, unique identifier) 252  18 Limit 16 to (English language and humans) 3,351,279  20 Limit 18 to (English language and humans) 3,351,279  21 2 or 4 or 6 or 8 15,243  22 10 or 12 or 14 or 16 3,351,279  23 and 24 3,361,279	#	Searches	Results
Polyphenol.mp. (mp = title, abstract, original title, name of substance word, subject disease supplementary concept word, unique identifier)  4 Limit 3 to (English language and humans)  5 Flavonoid.mp (mp = title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier)  6 Limit 5 to (English language and humans)  7 or *chalcones/ or *flavanones/ or *flavonos/ or *flavonoids/ or * catechin/ or *chalcones/ or *flavanones/ or *flavonoids/ or * flavonoids/ or * soflavones/ or *flavonoids/ or * soflavones/ or *flavonoids/ or * soflavones/ or *flavonoids/ or * soflavones/ or *flavones/ or *flavonoids/ or * soflavones/ or *flavones/ or *flavonoids/ or * soflavones/ or * flavonoids/ or * soflavonoids/ or * sofl	1	* Polyphenols	1238
heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier)  Limit 3 to (English language and humans)  Plavonoid.mp (mp = title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier)  Limit 5 to (English language and humans)  *flavonoids/ or * anthocyanins/ or * benzoflavones/ or * bioflavonoids/ or * catechin/ or * chalcones/ or * flavanones/ or * flavonos/ or * flavonolignans/ or * flavonols/ or * isoflavones/ or * flavonoids/ or * catechin/ or * chalcones/ or * flavanones/ or * flavonoids/ or * flavonoids/ or * isoflavones/ or * flavonoids/ or * flavonoids/ or * isoflavones/ or * flavonoids/ or * flavonoids/ or * isoflavones/ or * flavonoids/ or * flavonoids/ or * isoflavones/ or * flavonoids/ or * flavonoids/ or * isoflavones/ or * flavonoids/ or * flavonoids/ or * isoflavones/ or * flavonoids/ or * flavonoids/ or * isoflavones/ or * flavonoids/ or * isoflavonoids/ or * isoflavones/ or * flavonoids/ or * isoflavones/ or * flavonoids/ or * isoflavones/ or * flavonoids/ or * isoflavonoids/ or * catechin/ or * chalcones/ or * flavonoids/ or * isoflavonoids/ or * catechin/ or * catechin/ or * catechin/ or * chalcones/ or * flavonoids/ or * catechin/ or * cat	2	Limit 1 to (English language and humans)	594
disease supplementary concept word, unique identifier)  Limit 3 to (English language and humans)  Flavonoid.mp (mp = title, abstract, original title, name of substance word, subject  heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier)  Limit 5 to (English language and humans)  *flavonoids/ or * anthocyanins/ or * benzoflavones/ or * bioflavonoids/ or * catechin/ or * chalcones/ or * flavanones/ or * flavones/ or * flavonolignans/ or * flavonols/ or * 35,617  isoflavones/ or * proanthocyanidins/  Limit 7 to (English language and humans)  Limit 7 to (English language and humans)  Limit 9 to (English language and humans)  Tip336  Limit 19 to (English language and humans)  Limit 11 to (English language and humans)  Night 1 * Inflammation/  Limit 11 to (English language and humans)  Oxidative stress.mp (mp = title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier)  Limit 13 to (English language and humans)  56,835  Inflammat *.mp (mp = title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier)  Limit 14 to (English language and humans)  56,835  Limit 16 to (English language and humans)  393,710  *Adult/  20 Limit 18 to (English language and humans)  393,710  Limit 18 to (English language and humans)  335,1279  Limit 18 to (English language and humans)  3,331,279  Limit 18 to (English language and humans)  3,331,279  Limit 10 or 12 or 14 or 16  3,331,279  21 and 22  2757		Polyphenol.mp. (mp = title, abstract, original title, name of substance word, subject	
4 Limit 3 to (English language and humans)  Flavonoid, mp (mp = title, abstract, original title, name of substance word, subject  beading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier)  6 Limit 5 to (English language and humans)  * flavonoids/ or * anthocyanins/ or * benzoflavones/ or * bioflavonoids/ or * catechin/ or * chalcones/ or * flavanones/ or * flavones/ or * flavonolignans/ or * flavonols/ or * 35,617  isoflavones/ or * proanthocyanidis/  8 Limit 7 to (English language and humans)  12,245  9 * Oxidative Stress/  37,608  10 Limit 9 to (English language and humans)  17,936  11 * Inflammation/  40,537  12 Limit 11 to (English language and humans)  Oxidative stress.mp (mp = title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier)  14 Limit 13 to (English language and humans)  Inflammat *.mp (mp = title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, varied disease supplementary concept word, unique identifier)  15 Limit 14 to (English language and humans)  Sof,835  Inflammat *.mp (mp = title, abstract, original title, name of substance word, subject disease supplementary concept word, unique identifier)  16 Limit 14 to (English language and humans)  393,710  7 * Adult/  523  265  Adult.mp (mp = title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier)  20 Limit 18 to (English language and humans)  3,351,279  21 2 or 4 or 6 or 8  15,243  22 10 or 12 or 14 or 16  438,394  23 18 or 20  3,351,279	3		6327
Flavonoid.mp (mp = title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier)  6 Limit 5 to (English language and humans)  7 a flavonoids/ or * anthocyanins/ or * benzoflavones/ or * bioflavonoids/ or * catechin/ or * chalcones/ or * flavanones/ or * flavonolignans/ or * flavonols/ or * a5,617 isoflavones/ or * proanthocyanidins/  8 Limit 7 to (English language and humans)  12 Limit 9 to (English language and humans)  13 * Inflammation/  14 Limit 11 to (English language and humans)  15 Coxidative stress, mp (mp = title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier)  14 Limit 13 to (English language and humans)  15 Limit 13 to (English language and humans)  16 Limit 13 to (English language and humans)  17 * Adult/  18 Adult/  29 Adult/  20 Limit 14 to (English language and humans)  20 Limit 14 to (English language and humans)  30 Jay 10 September 10 Sept		disease supplementary concept word, unique identifier)	
heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier)  Limit 5 to (English language and humans)  *flavonoids/ or * anthocyanins/ or * benzoflavones/ or * bioflavonoids/ or * catechin/ or * chalcones/ or * flavanones/ or * flavonos/ or * flavonols/ or * 35,617  isoflavones/ or * proanthocyanidins/  Limit 7 to (English language and humans)  Limit 9 to (English language and humans)  Limit 9 to (English language and humans)  Limit 9 to (English language and humans)  Noxidative Stress/  Oxidative Stress, mp (mp = title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier)  Limit 13 to (English language and humans)  56,835  Inflammat *.mp (mp = title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier)  Limit 13 to (English language and humans)  56,835  Limit 16 to (English language and humans)  7 * Adult/  * Adult/ * 523  Limit 16 to (English language and humans)  20 Limit 18 to (English language and humans)  21 * 20 * 4 * or 6 * or 8  22 * Limit 18 * to (English language and humans)  33,351,279  24 * 21 * and 22  25757	4		2215
disease supplementary concept word, unique identifier)  6 Limit 5 to (English language and humans)  * flavonoids/ or * anthocyanins/ or * benzoflavones/ or * bioflavonoids/ or * catechin/  7 or * chalcones/ or * flavanones/ or * flavonolignans/ or * flavonols/ or *  isoflavones/ or * proanthocyanidins/  8 Limit 7 to (English language and humans)  12,245  9 * Oxidative Stress/  37,608  10 Limit 9 to (English language and humans)  11,7936  11 * Inflammation/  12 Limit 11 to (English language and humans)  13 subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier)  14 Limit 13 to (English language and humans)  56,835  Inflammat *.mp (mp = title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, unique identifier)  14 Limit 13 to (English language and humans)  56,835  Inflammat *.mp (mp = title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier)  16 Limit 14 to (English language and humans)  393,710  17 * Adult/  523  18 Limit 16 to (English language and humans)  265  Adult.mp (mp = title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier)  20 Limit 18 to (English language and humans)  3,351,279  21 2 or 4 or 6 or 8  15,243  22 10 or 12 or 14 or 16  438,394  23 18 or 20  3,351,279  24 21 and 22			
6 Limit 5 to (English language and humans)  * flavonoids/ or * anthocyanins/ or * benzoflavones/ or * bioflavonoids/ or * catechin/ or * chalcones/ or * flavanones/ or * flavonos/ or * flavonolignans/ or * flavonols/ or * isoflavones/ or * proanthocyanidins/  8 Limit 7 to (English language and humans)  12,245  9 * Oxidative Stress/ 37,608  10 Limit 9 to (English language and humans)  11,7936  11 * Inflammation/ 20,237  12 Limit 11 to (English language and humans)  13 subject heading word, keyword heading word, protocol supplementary concept word, unique identifier)  14 Limit 13 to (English language and humans)  56,835  Inflammat *.mp (mp = title, abstract, original title, name of substance word, subject heading word, keyword heading word, unique identifier)  14 Limit 13 to (English language and humans)  56,835  Inflammat *.mp (mp = title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier)  16 Limit 14 to (English language and humans)  393,710  17 * Adult/  523  18 Limit 16 to (English language and humans)  265  Adull.mp (mp = title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier)  20 Limit 18 to (English language and humans)  3,351,279  21 2 or 4 or 6 or 8  15,243  22 10 or 12 or 14 or 16  438,394  23 18 or 20  335,677	5		10,924
* flavonoids/ or * anthocyanins/ or * benzoflavones/ or * bioflavonoids/ or * catechin/ or * chalcones/ or * flavanones/ or * flavonos/ or * flavonolignans/ or * flavonols/ or * isoflavones/ or * proanthocyanidins/  8 Limit 7 to (English language and humans) 12,245 9 * Oxidative Stress/ 37,608 10 Limit 9 to (English language and humans) 11 * Inflammation/ 12 Limit 11 to (English language and humans) 23,251 Oxidative stress.mp (mp = title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier) 14 Limit 13 to (English language and humans) 56,835 Inflammat *.mp (mp = title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier) 15 heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier) 16 Limit 14 to (English language and humans) 393,710 17 * Adult/ 523 18 Limit 16 to (English language and humans) 265 Adult.mp (mp = title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier) 20 Limit 18 to (English language and humans) 3,351,279 21 2 or 4 or 6 or 8 15,243 22 10 or 12 or 14 or 16 438,394 23 18 or 20 21 and 22 2757			
or * chalcones/ or * flavanones/ or * flavanones/ or * flavonolignans/ or * flavonols/ or * isoflavones/ or * proanthocyanidins/  8 Limit 7 to (English language and humans) 12,245 9 * Oxidative Stress/ 37,608 10 Limit 9 to (English language and humans) 11 * Inflammation/ 12 Limit 11 to (English language and humans) 23,251 Oxidative stress.mp (mp = title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier) 14 Limit 13 to (English language and humans) 56,835 Inflammat *.mp (mp = title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier) 15 heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier) 16 Limit 14 to (English language and humans) 393,710 17 * Adult/ 523 18 Limit 16 to (English language and humans) 265 Adult.mp (mp = title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier) 20 Limit 18 to (English language and humans) 3,351,279 21 2 or 4 or 6 or 8 15,243 22 10 or 12 or 14 or 16 438,394 23 18 or 20 3,351,279 24 21 and 22	6		3212
isoflavones/ or * proanthocyanidins/  8 Limit 7 to (English language and humans)  9 * Oxidative Stress/  10 Limit 9 to (English language and humans)  11,936  11 * Inflammation/  23,251  Oxidative stress.mp (mp = title, abstract, original title, name of substance word,  13 subject heading word, keyword heading word, protocol supplementary concept  word, rare disease supplementary concept word, unique identifier)  14 Limit 13 to (English language and humans)  56,835  Inflammat *.mp (mp = title, abstract, original title, name of substance word, subject  15 heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier)  16 Limit 14 to (English language and humans)  77 * Adult/  8 Limit 16 to (English language and humans)  Adult.mp (mp = title, abstract, original title, name of substance word, subject heading  word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier)  18 Limit 16 to (English language and humans)  393,710  20 Limit 18 to (English language and humans)  305,710  21 Limit 18 to (English language and humans)  305,710  22 Limit 18 to (English language and humans)  307,710  308,710  309,710  309,710  309,710  309,710  309,710  309,710  309,710  309,710  309,710  309,710  309,710  309,710  309,710  309,710  309,710  309,710  309,710  309,710  309,710  309,710  309,710  309,710  309,710  309,710  309,710  309,710  309,710  309,710  309,710  309,710  309,710  309,710  309,710  309,710  309,710  309,710  309,710  309,710  309,710  309,710  309,710  309,710  309,710  309,710  309,710  309,710  309,710  309,710  309,710  309,710  309,710  309,710  309,710  309,710  309,710  309,710  309,710  309,710  309,710  309,710  309,710  309,710  309,710  309,710  309,710  309,710  309,710  309,710  309,710  309,710  309,710  309,710  309,710  309,710  309,710  309,710  309,710  309,710  309,710  309,710  309,710  309,710  309,710  309,710  309,710  309,710  309,710  309,710  309,710  309			
8 Limit 7 to (English language and humans) 12,245 9 *Oxidative Stress/ 37,608 10 Limit 9 to (English language and humans) 17,936 11 *Inflammation/ 40,537 12 Limit 11 to (English language and humans) 23,251 Oxidative stress.mp (mp = title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier) 14 Limit 13 to (English language and humans) 56,835 Inflammat *.mp (mp = title, abstract, original title, name of substance word, subject 15 heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier) 16 Limit 14 to (English language and humans) 393,710 17 *Adult/ 523 18 Limit 16 to (English language and humans) Adult.mp (mp = title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, unique identifier) 20 Limit 18 to (English language and humans) 3,351,279 21 2 or 4 or 6 or 8 15,243 22 10 or 12 or 14 or 16 438,394 23 18 or 20 3,351,279 24 21 and 22 2757	7		35,617
9 *Oxidative Stress/ 37,608  10 Limit 9 to (English language and humans) 17,936  11 *Inflammation/ 40,537  12 Limit 11 to (English language and humans) 23,251  Oxidative stress.mp (mp = title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier)  14 Limit 13 to (English language and humans) 56,835  Inflammat *.mp (mp = title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier)  15 heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier)  16 Limit 14 to (English language and humans) 393,710  17 *Adult/ 523  18 Limit 16 to (English language and humans) 265  Adult.mp (mp = title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier)  20 Limit 18 to (English language and humans) 3,351,279  21 2 or 4 or 6 or 8 15,243  22 10 or 12 or 14 or 16 438,394  23 18 or 20 3,351,279  24 21 and 22 2757		isoflavones/ or * proanthocyanidins/	
10Limit 9 to (English language and humans)17,93611* Inflammation/40,53712Limit 11 to (English language and humans)23,251Oxidative stress.mp (mp = title, abstract, original title, name of substance word,13subject heading word, keyword heading word, protocol supplementary concept127,345word, rare disease supplementary concept word, unique identifier)56,835Inflammat *.mp (mp = title, abstract, original title, name of substance word, subject678,94815heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier)678,94816Limit 14 to (English language and humans)393,71017* Adult/52318Limit 16 to (English language and humans)265Adult.mp (mp = title, abstract, original title, name of substance word, subject heading4,443,010word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier)4,443,01020Limit 18 to (English language and humans)3,351,279212 or 4 or 6 or 815,2432210 or 12 or 14 or 16438,3942318 or 203,351,2792421 and 222757	8	, ,	12,245
11 *Inflammation/ 40,537 12 Limit 11 to (English language and humans) 23,251  Oxidative stress.mp (mp = title, abstract, original title, name of substance word, 13 subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier)  14 Limit 13 to (English language and humans) 56,835  Inflammat *.mp (mp = title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier)  16 Limit 14 to (English language and humans) 393,710  17 *Adult/ 523  18 Limit 16 to (English language and humans) 265  Adult.mp (mp = title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier)  20 Limit 18 to (English language and humans) 3,351,279  21 2 or 4 or 6 or 8 15,243  22 10 or 12 or 14 or 16 438,394  23 18 or 20 3,351,279  24 21 and 22 2757	9	* Oxidative Stress/	37,608
12 Limit 11 to (English language and humans)  Oxidative stress.mp (mp = title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier)  14 Limit 13 to (English language and humans)  Inflammat *.mp (mp = title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier)  16 Limit 14 to (English language and humans)  7 * Adult/  8 Limit 16 to (English language and humans)  Adult.mp (mp = title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier)  20 Limit 18 to (English language and humans)  3,351,279  21 2 or 4 or 6 or 8  15,243  22 10 or 12 or 14 or 16  438,394  23 18 or 20  3,351,279  24 21 and 22  2757	10	Limit 9 to (English language and humans)	17,936
Oxidative stress.mp (mp = title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier)  14 Limit 13 to (English language and humans) Inflammat *.mp (mp = title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier)  16 Limit 14 to (English language and humans) 393,710  17 *Adult/ 523  18 Limit 16 to (English language and humans) 265 Adult.mp (mp = title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier)  20 Limit 18 to (English language and humans) 3,351,279  21 2 or 4 or 6 or 8 15,243  22 10 or 12 or 14 or 16 438,394  23 18 or 20 3,351,279  24 21 and 22 2757	11	* Inflammation/	40,537
subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier)  Limit 13 to (English language and humans)  Inflammat *.mp (mp = title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier)  Limit 14 to (English language and humans)  393,710  Limit 16 to (English language and humans)  Adult.mp (mp = title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier)  Limit 18 to (English language and humans)  3,351,279  Limit 18 to (English language and humans)  3,351,279  10 or 12 or 14 or 16  438,394  18 or 20  3,351,279  24 21 and 22  2757	12	Limit 11 to (English language and humans)	23,251
word, rare disease supplementary concept word, unique identifier)  14 Limit 13 to (English language and humans)  Inflammat *.mp (mp = title, abstract, original title, name of substance word, subject  15 heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier)  16 Limit 14 to (English language and humans)  17 * Adult/  18 Limit 16 to (English language and humans)  265  Adult.mp (mp = title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier)  20 Limit 18 to (English language and humans)  3,351,279  21 2 or 4 or 6 or 8  15,243  22 10 or 12 or 14 or 16  438,394  23 18 or 20  3,351,279  24 21 and 22  2757			
Limit 13 to (English language and humans)  Inflammat *.mp (mp = title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier)  Limit 14 to (English language and humans)  Limit 16 to (English language and humans)  Adult.mp (mp = title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier)  Limit 18 to (English language and humans)  Jay1710  Limit 18 to (English language and humans)  Limit 18 to (English language and humans)  Jay1710  Limit 18 to (English language and humans)  Jay1710  Limit 18 to (English language and humans)  Jay1710	13		127,345
Inflammat *.mp (mp = title, abstract, original title, name of substance word, subject  15 heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier)  16 Limit 14 to (English language and humans)  17 * Adult/  18 Limit 16 to (English language and humans)  265  Adult.mp (mp = title, abstract, original title, name of substance word, subject heading  word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier)  20 Limit 18 to (English language and humans)  3,351,279  21 2 or 4 or 6 or 8  15,243  22 10 or 12 or 14 or 16  438,394  23 18 or 20  3,351,279  24 21 and 22  2757			
heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier)  16 Limit 14 to (English language and humans)  17 *Adult/  18 Limit 16 to (English language and humans)  265  Adult.mp (mp = title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier)  20 Limit 18 to (English language and humans)  21 2 or 4 or 6 or 8  22 10 or 12 or 14 or 16  33351,279  3351,279  3351,279  24 21 and 22  2757	14		56,835
disease supplementary concept word, unique identifier)  16 Limit 14 to (English language and humans)  17 * Adult/  18 Limit 16 to (English language and humans)  265  Adult.mp (mp = title, abstract, original title, name of substance word, subject heading  19 word, keyword heading word, protocol supplementary concept word, rare disease  supplementary concept word, unique identifier)  20 Limit 18 to (English language and humans)  21 2 or 4 or 6 or 8  22 10 or 12 or 14 or 16  438,394  23 18 or 20  3,351,279  24 21 and 22  2757			
16Limit 14 to (English language and humans)393,71017* Adult/52318Limit 16 to (English language and humans)265Adult.mp (mp = title, abstract, original title, name of substance word, subject heading19word, keyword heading word, protocol supplementary concept word, rare disease4,443,010supplementary concept word, unique identifier)20Limit 18 to (English language and humans)3,351,279212 or 4 or 6 or 815,2432210 or 12 or 14 or 16438,3942318 or 203,351,2792421 and 222757	15		678,948
17* Adult/52318Limit 16 to (English language and humans)265Adult.mp (mp = title, abstract, original title, name of substance word, subject heading4,443,01019word, keyword heading word, protocol supplementary concept word, rare disease4,443,010supplementary concept word, unique identifier)3,351,279212 or 4 or 6 or 815,2432210 or 12 or 14 or 16438,3942318 or 203,351,2792421 and 222757			
18Limit 16 to (English language and humans)265Adult.mp (mp = title, abstract, original title, name of substance word, subject heading19word, keyword heading word, protocol supplementary concept word, rare disease4,443,010supplementary concept word, unique identifier)20Limit 18 to (English language and humans)3,351,279212 or 4 or 6 or 815,2432210 or 12 or 14 or 16438,3942318 or 203,351,2792421 and 222757	16		
Adult.mp (mp = title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier)  20 Limit 18 to (English language and humans)  21 2 or 4 or 6 or 8  22 10 or 12 or 14 or 16  438,394  23 18 or 20  3,351,279  24 21 and 22  2757	17	* Adult/	523
19       word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier)       4,443,010         20       Limit 18 to (English language and humans)       3,351,279         21       2 or 4 or 6 or 8       15,243         22       10 or 12 or 14 or 16       438,394         23       18 or 20       3,351,279         24       21 and 22       2757	18		265
supplementary concept word, unique identifier)         20       Limit 18 to (English language and humans)       3,351,279         21       2 or 4 or 6 or 8       15,243         22       10 or 12 or 14 or 16       438,394         23       18 or 20       3,351,279         24       21 and 22       2757			
20       Limit 18 to (English language and humans)       3,351,279         21       2 or 4 or 6 or 8       15,243         22       10 or 12 or 14 or 16       438,394         23       18 or 20       3,351,279         24       21 and 22       2757	19	, , , , ,	4,443,010
21       2 or 4 or 6 or 8       15,243         22       10 or 12 or 14 or 16       438,394         23       18 or 20       3,351,279         24       21 and 22       2757			
22       10 or 12 or 14 or 16       438,394         23       18 or 20       3,351,279         24       21 and 22       2757	20		
23     18 or 20     3,351,279       24     21 and 22     2757	21		
24 21 and 22 2757	22	10 or 12 or 14 or 16	438,394
	23		3,351,279
25 23 and 24 308	24	21 and 22	2757
	25	23 and 24	308

<sup>\*</sup> Prior to the search term means that the term was searched as a MeSH term; \* Post term is a truncation of the term to enable multiple endings of the term to be included. E.g. inflammatat \* includes inflammation, inflammatory etc.

### **Cochrane Library**

Title, Abstra	act, Keywords	(Polyphenol or Flavonoid or Anthocyanin or Catechin or Flavon* or isoflavon* or benzoflavone or proanthrocyanidin)
And	Title, Abstract, Keywords	Oxidative stress or inflammat*
And	Search All Text	Adult or Aged

All Results: 289 Cochrane Reviews: 2

Trials: 285

### Cinahl

#	Search	Search Options	Results
	TX polyphenol or TX flavonol or TX		
1	anthrocyanin or TX isoflavn* or TX	Search modes-Boolean/Phrase	2055
	benzoflavone or TX proanthrocyandin		
2	TX oxidative stress or TX inflammat*	Search modes-Boolean/Phrase	46,185
3	1 and 2	Search modes-Boolean/Phrase	304
4	TX adult	Search modes-Boolean/Phrase	752,195
5	TX adult or TX aged	Search modes-Boolean/Phrase	771,922
6	3 and 5	Search modes-Boolean/Phrase	78

### Scopus

(Polyphenol or Flavonoid or Anthocyanin or Catechin or Flavon* or isoflavon* or benzoflavone or proanthrocyanidin)		Article Title, Abstract, Keywords
And	Oxidative stress or inflammat*	Article Title, Abstract, Keywords
And	Adult or Aged	Article Title, Abstract, Keywords

Limit to: language, "English" and exactkeyword, "Human"

Results: 573

All articles found from the database searches above were imported into an Endnote database. The articles were then filtered as per Figure 2 on page 5 of the manuscript.

In reference to 2.5 Quality assessments, the final Cochrane Collaboration quality assessment tables below were used report on the quality of the studies. The tables below include collated points and judgment of both reviewers.

The Cochrane Collaboration's	Tool for Assessing Risk of Bias	Study Design: Double-Blinded Randomised Controlled Cross over
	ith, K.A.; Kilpatrick, E.S.; Atkin, S.L. High-polyphenol chocolate reduces endotheli be 2 diabetes: A pilot randomized controlled trial. <i>Diabet. Med.</i> <b>2013</b> , <i>30</i> , 478–483.	ial dysfunction and oxidative stress during acute
Domain	Support for Judgment	Review Authors' Judgment
Selection bias		
Random sequence generation	States randomization code was held at chocolate provider (Barry Callebaut) (p. 480).	Unclear risk of bias as method of generating the randomization code was not provided. Therefore not enough information is provided to determine if method used is at risk of bias.
Allocation concealment	"Barry Callebaut provided both chocolates in identical presentation". (p. 480).	This suggests that allocation concealment may have occurred, however no information was provided on allocation concealment. Unclear risk of bias.
Performance bias		
Blinding of participants and personnel	States it is a double-blinded study.	
(Assessments should be made for each main outcome or class of outcomes)	Intervention was identical in appearance, composition (exception of polyphenol content) and packaging. Only potential is a difference in taste which was not mentioned, thus likelihood is low.	Low risk of bias.
Detection bias		
Blinding outcome assessment	States it is a double-blinded study.	
(Assessments should be made for each main outcome or class of outcomes)	Says that they are blinded but due to lack of information, unsure if method used disables researchers awareness of the intervention provided. However if not blinded properly, unlikely to affect results, as they are objective measures.	Low risk of bias.
Attrition bias		
Incomplete outcome data	No dropouts reported. Data reported for the 10 participants that underwent the randomization and allocation as evidenced by flow chart on page 479.	Lead of the second of the Bank
(Assessments should be made for each main outcome or class of outcomes)	Excluded one participant at screening due to anaemia (p. 479).	<ul> <li>Low risk of bias, as data was reported for all 10 participants.</li> </ul>
Reporting bias		
Selective reporting	Outcomes as per methods Reported in results (Yes/No) Endothelial function measured by the EndoPAT.  Reported in results (Yes/No) Yes (p. 480).	<ul> <li>Low risk of bias as all outcomes reported as per the study method.</li> </ul>

Healthcare <b>2016</b> , 4, 69		S4 of S40
	Oxidative stress measured by Yes (p. 480). Urinary 25-F2t isoprostane: creatinine.	
Other bias		
Other sources of bias	Carry over effect "One month prior to crossover" (p. 479).  Confounding: "2-week pre-start washout period where they abstained from rich sources of polyphenol (using a list of foods provided) and omitted all chocolate and cocoa" (p. 479). 1 week post intervention period 1 washout (p. 480). States: "To assess dietary adherence and reduce the potential confounding resulting from a change in background diet, dietary intake was recorded using 24-h dietary recall by study dietitian. (p. 480)." State: "Dietary analysis and assessment of physical activity levels showed no significance intra-subject differences between the two groups." (p. 481).  Power calculation: "A power calculation was undertaken based upon the data of Balzer et al using G* Power which suggested a minimum sample size of seven (based on a difference of 1.8 in endothelial function, power = 0.80 for alpha <0.05). Fasting endothelial function was $1.7 \pm 0.1$ and $2.3 \pm 0.1$ 180 min after chocolate consumption. With a % change $p = 0.03$ )."  Source of funding: "funded by Barry Callebaut Beglium NV, but study design and analysis were undertaken independently by the research team." Did not declare and competing interests. (p. 482).  Site of recruitment: Not stated.  Adherence or compliance: "To assess dietary adherence and reduce the potential confounding resulting from a change in background diet" (p. 480).	<ul> <li>Low risk of bias due to the following:</li> <li>Considered sources of confounding such as diet and physical activity which ensures participants have the same diet before each intervention period and assessed adherence to this diet.</li> <li>Considered potential carry over effect and implemented a washout period.</li> <li>Suggest that industrial funding does not influence results.</li> <li>Risk of type 1 error is 0.03 as changes in endothelial function observed are smaller than anticipated (0.6 seen vs. 1.8 anticipated) however confidence intervals are quite small suggesting that effect is present but may not be statistically significant.</li> </ul>
Overall risk of bias		Low risk of bias considering that all data collected was objective measures that were all reported. Study design controlled for potential confounder and carry over effect. Study design suggests adequate participant blinding as chocolate was provided by chocolate provider in identical presentation. Slight risk of potential selection and detection bias may have occurred due to the inadequate information provided but risk considered small as all outcomes were reported.

The Cochrane Collaboration's Too	Study Design: Randomised Single-Blinded Cross over Study	
=	edo, L.; Pignatelli, P.; Nocella, C.; Bartimoccia, S.; di Santo, S.; Ma OX2 down-regulation in smokers. <i>J. Thromb. Haemost.</i> <b>2012</b> , <i>10</i> , 12	
Domain	Support for judgment	Review authors' judgment
Selection bias		
Random sequence generation	"They were randomly allocated to a treatment sequence with 40 g of dark chocolate (≥85% cocoa) or milk chocolate (≤35% cocoa in a cross over, single blind design' (p. 126).  'The randomization was carried out by a procedure based on a random numeric sequence" (p. 126).	Low risk of bias as random numeric sequence was used.
Allocation concealment	"An individual not involved in the study, assigned codes to the study treatments, randomly allocated the participants to a treatment sequence with dark or milk chocolate and kept the key in sealed envelope."  "The authors and laboratory technicians were unaware of the treatment allocation." (p. 126).	Low risk of bias as individual not involved in the study conducted allocation and used sealed, key kept in envelope and states that investigators measuring outcome were unaware of allocation.
Performance bias		
Plinding of participants and personnel (Assessments should be made for each main outcome or class of outcomes)	"Intrinsic difficulties in performing a double-blind study with dark and milk chocolate. (p. 131)."	High risk of bias as method to mask the different appears of treatment was not conducted.
Detection bias		
Blinding outcome assessment  (Assessments should be made for each main outcome or class of outcomes)	States: "blind laboratory analysis" (p. 131) and "single blinded study" (p. 126).	Low risk of bias as this suggests that laboratory technicians who have not collected the data, conducted the laboratory analysis. This reduces any potential risk of bias associated with unmasked participants accidently expressing their treatment allocation to investigators.
Attrition bias		
Incomplete outcome data	Dropouts not mentioned in methods and result	Unclear risk of bias as no dropouts and number of

11euitheure <b>2010</b> , 4, 09			50 01 5	
(Assessments should be made for	(pp. 126–127).		participants used in analysis not stated (p. 128).	
each main outcome or class of				
outcomes)	(pp. 127–129)			
Reporting bias				
	Outcomes as per methods	Reported in results (Yes/No)	Demonts described and the second seco	
Selective reporting	Platelet function	Yes (p. 128)	<ul><li>Reported on all outcome measures reported.</li><li>Low risk of bias</li></ul>	
	Oxidative stress measured by Platelet 8-iso-PGF2 $\alpha$ assay	Yes (p. 128)	- Low risk of bias	
Other bias				
	Carry over effect: "There was a the two phases of the study." (p	3	Suggest low risk of bias as study: - Reduced carry over effect by providing a washou	
	Confounding: "Furthermore, there were no significant differences in caloric content between the dark (Calories 230) and milk (Calories 220) chocolate." (p. 126).		<ul><li>period between interventions</li><li>Considered impact of calories from different chocolates being a source of confounding</li></ul>	
Other sources of bias	Power calculation: "difference variation in smokers to be detected chocolate treatments and paired error probability =0.05 and power (p. 127).	cted between dark and milk d differed SD = 5 and type I	<ul> <li>SD observed in outcome used for power calculation met prediction and this probability of type 1 error is 0.05</li> <li>Source of funding was not stated but authors declare no conflict of interest.</li> </ul>	
	Source of funding: "The authors state that they have no conflict of interest" (p. 131).		<ul> <li>Measuring adherence to study product was no applicable as intervention only provided on or</li> </ul>	
	Site of recruitment: Not stated.		occasion and provided by investigators.	
	Adherence/compliance: Not stated		No dietary assessment to measure compliance polyphenol-free diet in 24 h prior to measurement.	
Overall risk of bias			Low risk of bias as unmasked participants are unlikely to affect objective outcome measures assessed. As dropouts were not reported, it's likely there were no dropouts and analysis was performed on all participants.	

The Cochrane Collaboration's Tool for Asses	Study Design: Randomised, Placebo-Controlled Double-Blind Cross over Study	
<b>Study Details:</b> Mellor, D.D.; et al. High-cocoa 1318–1321.	polyphenol-rich chocolate improves HDL cholesterol in Type 2 diabe	tes patients. <i>Diabet. Med.</i> <b>2010</b> , 27,
Domain	Support for judgment	Review authors' judgment
Selection bias		
Random sequence generation	'Randomisation was undertaken by Nestec Ltd with enough chocolate being given to subjects for 8-week period (p. 1319)'.	Unclear risk of bias as method of randomisation is not provided.
Allocation concealment	Not stated	Unclear risk of bias as information of allocation concealment was not stated.
Performance bias		
Blinding of participants and personnel (Assessments should be made for each main outcome or class of outcomes)	States it's a double-blinded study (p. 1318), "dyed to the same colour as high polyphenol chocolate" (p. 1319). "a blinded taste study was undertaken prior to the trial that showed that the subjects could not tell any difference in appearance or taste between the high-polyphenol chocolate and the low-polyphenol chocolate preparations (p. 1320)."	Low risk of bias as blinded taste test was conducted.
Detection bias		
Blinding outcome assessment (Assessments should be made for each main outcome or class of outcomes)	States it's a double-blinded study (p. 1318).  Objective outcome assessment performed:  - fasting blood samples of total cholesterol, triglyceride and HDL cholesterol levels, plasma glucose, serum insulin, HbA1c, CRP  - Blood pressure  - Weight	Although method of blinding is not reported, due to the objective nature of the outcome measures assessment, detection is unlikely to affect the results.  Low risk of bias

Incomplete outcome data (Assessments should be made for each main outcome or class of outcomes)	Drop outs not mentioned in "twelve subjects were enrol 1318). All twelve study part drop-outs and no reported subjective outcomes. The nuthe treatment and control gunlikely to influence the res	Low risk of bias	
Reporting bias			
	Outcomes as per methods	Reported in results (Yes/No)	_ All outcomes intended in methods
	Weight	Yes (p. 1320)	were reported.
Selective reporting	Glycaemic control	Yes (p. 1320)	Low risk of bias
	Lipid profile	Yes (p. 1320)	3-month lipids checked, no
	High-sensitivity CRP	Yes (p. 1320)	difference and not reported.
Other bias			
	Carry over effect: States: "crossed over after 4week washout period (p. 1318)."  Confounding: States: "Subjects were advised not to consume any other chocolate for the duration of the study, apart from this, subject were instructed to make no further changes to their diet and lifestyle (p. 1318)."		Low risk of bias as study accounted for:  - Carry over effects - Confounding due to diet and lifestyle - Change of >0.4mmol/L seen in plasma HDL.
Other sources of bias	Power calculation: "At $p < 0.05$ level of significance, a sample size of 12 subjects in a crossover fashion will provide >90% power to detect a 0.4 mmol/L change in plasma HDL cholesterol concentration." (p. 1319).		
	Source of funding: "The chocolate for the study was provided as an unrestricted gift from Nestle PTC, York and was funded through the Diabetes Research and Development fund (p. 1318)."  Site of recruitment: Not stated.		<ul> <li>Assess adherence</li> <li>Intervention product provided</li> <li>as a gift</li> </ul>
	Adherence/compliance: "To monitor compliance, subjects were asked to return all empty wrappers, noting the time and date when it was consumed on the wrapper. (p. 1319)."		
Overall risk of bias			Low risk of bias

The Cochrane Collaboration's Tool for Assessing Risk of Bias			Study Design: Randomised, Controlled, Cross-over, Free-Living Study	
<b>Study Details:</b> Sarria, B.; Martinez-Lopez, S.; Sie cardiometabolic profile in healthy and moderate			ular consumption of a cocoa product improves the	
Domain	Support for judgment	uns. Dr. J. Muir. <b>2014</b> , 111, 1	Review authors' judgment	
Selection bias	Support for Judgment		Keview authors juugment	
Random sequence generation	"Randomised, controlled study (p. 122)".	l, cross-over, free-living	Unclear risk of bias as method of randomization is not provided.	
Allocation concealment	Not stated		Unclear risk of bias as information not provided	
Performance bias				
Blinding of participants and personnel (Assessments should be made for each main outcome or class of outcomes)	"The lack of blinding of subjects and investigators may have led to certain bias" (p. 132).  Participants may have altered their diet depending on treatment, however background diet was controlled for as a confounder and the crossover design would minimise the effect of this on the results.		Unclear risk of bias	
Detection bias				
Blinding outcome assessment (Assessments should be made for each main outcome or class of outcomes)	"the lack of blinding of subjects and investigators may have led to certain bias" (p. 132)  However this is unlikely to influence the results as all outcome measures are objective.		Low risk of bias	
Attrition bias				
Incomplete outcome data (Assessments should be made for each main outcome or class of outcomes)	"six withdraw due to personal, health or professional reasons (p. 126). Results as per tables provided results for only the 44 participants that completed the study (pp. 129–130)."		Low risk of bias as intention to treat analysis not required for due to cross over design and results table suggests that all participants that completed the study were included in the analysis.	
Reporting bias				
	Outcomes as per methods	Reported in results (Yes/No)	- Low risk of bias as reported on all outcomes	
Selective reporting	Serum lipid lipoprotein profile	Yes (p. 128)	measured	
	Oxidative stress	Yes (p. 130)		

	Inflammatory markers Yes (p. 129)	_
	Blood pressure Yes (p. 130)	
Other bias		
	Carry over effect: Wash out period not stated	
	Confounding: "After a 2-week run-in stage, in	
	which consumption of the fruit, vegetables and	
	beverage mentioned below was restricted." (p.	
	124). Their dietary intake was regularly evaluated	
	to control any possible changes. (p. 124).	
	Power calculation: Not stated	_
	Source of funding: Not stated	- I In along with a filing days to materatical assume account
Other sources of bias	Site of recruitment: 'Volunteer recruitment was	<ul> <li>Unclear risk of bias due to potential carry over effect</li> </ul>
	carried out by placing advertisements in the	effect
	Universidad Complutense campus as well as by	
	giving short talks between lectures.' (p. 123).	
	Adherence/compliance: "Compliance was	
	controlled by counting the number of cocoa	
	servings provided to the volunteers before and	
	after the interventions, as well as by weekly	
	calling the volunteers. (p. 124)."	
Overall risk of bias	-	Unclear risk of bias due to source of performance
Overall lisk of blas		and detection bias and potential carry over effects

The Cochrane Collaboration's Tool for Assessing Risk of Bias		Study Design: Randomised Double-Blinded Cross over Trial	
Study Details: Ruel, G.; Lapointe, A.; Pomerlea	u, S.; Couture, P.; Lemieux, S.; Lamarche, B.; Couillard, C	C. Evidence that cranberry juice may improve	
augmentation index in overweight men. Nutr. Res. 2013, 33, 41–49.			
Domain	Support for judgment	Review authors' judgment	
Selection bias			
Random sequence generation	States that "randomly assigned to drink 500 mL CJC/day (27% juice) or 500 mL placebo juice (PJ)/day for 4 weeks" (p. 41)	Unclear risk of bias as method of randomization not provided.	
Allocation concealment		Unclear risk of bias as information on potential allocation concealment not provided.	
Performance bias			
Blinding of participants and personnel (Assessments should be made for each main outcome or class of outcomes)	States that it is a double blind study (p. 41). "The CJC and PJ used in the present study had similar organoleptic properties (taste, colour and texture) and vitamin C contents but no cranberries entered in the parathion of the PJ. (p. 42)". "Both juices were packaged at Universite Laval in 125 mL ready-to drink TetraBrik boxes under the close monitoring of Ocean Spray to ensure adequate reconstitution and quality of the juices (p. 42)".	Low risk of bias as both interventions was similar in appearance.	
Detection bias  Blinding outcome assessment (Assessments should be made for each main outcome or class of outcomes)	States that it is a double blind study (p. 41).	Information on how investigators were masked was not provided but the results are unlikely to be affected if blinding was broken as the outcome measures are objective.  Low risk of bias.	
Attrition bias	3		
Incomplete outcome data (Assessments should be made for each main outcome or class of outcomes)	No dropouts reported. As per the result tables on pages 43–47, all participants were accounted for. No intention to treat analysis.	Low risk of bias as all outcome data collected was presented.	
Reporting bias			

Selective reporting	Outcome measured is AIx and cardiometabolic profile (p. 42). Not stated in methods what parameters are measured for the cardiometabolic profile (pp. 42–43).	Unclear risk of bias.
Other bias	, , , , , , , , , , , , , , , , , , ,	
Other sources of bias	Carry over effect: "Upon entry into the study, subjects were instructed by a dietician to maintain their usual nutritional habits, limit their alcohol consumption to a maximum of 1 drink per day as well as restrain themselves from consuming any vitamin, antioxidant or mineral supplements. (p. 42)" "following a run-in period of 4 weeks during which participants were asked to drink 500ml of water a day in order to get the subjects acquainted with the introduction of such an amount of liquid into their usual diet." (p. 42). "After a 4 week washout period (500 mL water/d), treatments were crossed over." (p. 42).  Confounding.  Power calculation: Not stated.  Source of funding: Canadian Institutes of Health Research. It is made clear that the organisations providing funding were not involved in the design or conduct of the study.  Site of recruitment: "through media" (p. 42).  Adherence/compliance: Not stated.	Unclear risk of bias as study design aimed to reduce carry over effects but not effects from potential confounding and adherence to intervention products.
Overall risk of bias		Unclear risk of bias of selection, detection, reporting and other bias due to lack of information provided.

The Cochrane Collaboration's Tool for Assessing Risk of Bias		Study Design: Randomised Dose-Response Controlled Trial
•	guyen, A.; Newman, E.D.; Fu, D.; Lyons, T.J. Freeze-dried stradiposity and elevated serum lipids. <i>J. Nutr.</i> <b>2014</b> , 144, 830–8	•
Domain	Support for judgment	Review authors' judgment
Selection bias		
Random sequence generation	"Randomly assigned to consume 1 of the following 4 beverages for 12 week" (p. 831).	Unclear risk of bias due to lack of information provided on randomization method.
Allocation concealment	Not stated	Unclear risk of bias due to lack of information provided
Performance bias		
Blinding of participants and personnel (Assessments should be made for each main outcome or class of outcomes)	"In addition, the control beverages contained added red food colour (McCormick & Company) and artificial strawberry-flavoured Kool-Aid (Kraft Foods) to mimic the colour and flavor of the FDS beverages. (p. 831). Absence of placebo agent that is identical to the FDS powder and could be used in a double-blind treatment (p. 835)."	Unclear risk of bias as this suggests that strategies to mask participants were put in place but detectable authors suggest that there may be detectable differences.
Detection bias		
Blinding outcome assessment (Assessments should be made for each main outcome or class of outcomes)	"All laboratory staff were unaware of the treatment groups. (p. 832)."	Low risk of bias
Attrition bias		
Incomplete outcome data (Assessments should be made for each main outcome or class of outcomes)	Not stated if intention to treat analysis was performed in methods or results (pp. 831–833). 85 participants tested, 66 met inclusion criteria (6 dropped out due to time constraints and 60 completed the study protocol. Not stated how many participants were initially randomised however reasons for drop outs are unrelated to the outcomes of interest and unlikely to affect the results. Data from all 60 participants appear to have been reported with no missing data.	Low risk of bias
Reporting bias		
Selective reporting	Reported on all outcomes anticipated.	Low risk of bias

Other bias		
	Carry over effect: not stated: N/A due to parallel design.	_
	Confounding: "The participants were instructed to add	
	the strawberry or control beverages as a snack to their	
	usual diet and not to replace it with any meals." "Asked	
	to refrain from consuming any other source of berries or	
	related products derived from berries, such as juices,	
	jams and desserts. Also asked to refrain from consuming	
	green tea, cocoa and soy products while participating in	
	the study. (pp. 831–832)." "Participants were instructed	
	to maintain their usual diet, physical activity, and	
	lifestyle while in the study. (p. 832)." "Control beverages	Low risk of bias due to study design accounting for
	were matched for calories and total fibre (p. 830)."	- Sources of confounding
	Power calculation: "Target sample size was calculated to	- Adherence to intervention
Other sources of bias	include 15 participants per group to detect minimum	- Potential carry over effects not applicable due to
	differences of 0.3 mmol/L in serum total cholesterol and	parallel design
	0.2 mmol/L in LDL cholesterol with 80% power based on	- Sample size meet and changes in TC and LDL
	out previous feasibility study" (p. 3).	- observed
	Source of funding/ conflict of interest: "received	
	monetary compensation during these weekly visits. (p.	
	831)."	-
	Site of recruitment: "Clinical Research Center in	
	University of Oklahoma Health Science Centre and	
	Nutritional Sciences Clinical Assessment Unit at	
	Oklahoma State University. (p. 831)."	-
	Adherence/compliance: "required to make 3 visit/wk to	
	their study site to ensure compliance by supervised	
	consumption on these days (p. 831)." "return any	
	unconsumed strawberry and control beverages (p. 831)."	

Low risk of bias

Overall risk of bias

The Cochrane Collaboration's Tool for Assessing Risk of Bias			Study Design: Randomised, Single-Blinded, Placebo Controlled, 12 Week Cross over Trial
Study Details: Burton-Freeman, B.; Linares, A.;	Hyson, D.; Kappagoda, T.	Strawberry modulates LDL or	xidation and postprandial lipemia in response to
high-fat meal in overweight hyperlipidemic me	n and women. J. Am. Coll.	Nutr. <b>2010</b> , 29, 46–54.	
Domain	Support for judgmen	t	Review authors' judgment
Selection bias			
Random sequence generation	"Randomised single-l week crossover trial (	olind, placebo-controlled, 12 p. 46)"	Unclear risk of bias as method of randomization not reported
Allocation concealment	Not stated		Unclear risk of bias as allocation concealment not reported
Performance bias			
Blinding of participants and personnel (Assessments should be made for each main outcome or class of outcomes)	States its single-blind (p. 46)		Suggests that participants are masked but method not reported. Unclear risk of bias
Detection bias			
Blinding outcome assessment (Assessments should be made for each main outcome or class of outcomes)	Not stated		Suggests that investigators we not masked but all outcome assessments were objective and thus lack of blinding should theoretically have little effect on the results.  Unclear risk of bias
Attrition bias			
Incomplete outcome data (Assessments should be made for each main outcome or class of outcomes)	Table on page 51 states " $n = 24$ ". "Twenty-four hyperlipidaemic men and women were recruited (p. 46)". There were 2 dropouts due to work commitments and caffeine withdrawal on postprandial testing days and there data was not included in the analysis.		Low risk of bias as all participants finished the trial and was included in the analysis. Dropouts were unrelated to study intervention. The inclusion of drop out data would have diluted the results.
Reporting bias			
Selective reporting	Outcomes as per Reported in results methods (Yes/No) Oxidative stress Yes (pp. 50–51)		Low risk of bias
Other bias		<b>X X</b> .	

Healthcare <b>2016</b> , 4, 69		S16 of S40
Other sources of bias	Carry over effect: "Subjects were transitioned immediately from one beverage to the next based on sequence randomization with no formal washout at crossover (p. 47)."  Confounding: "10-day run-in period (p. 46)." " to establish that there were no unanticipated changes in subjects' diets during the study period. (p. 48)."  The background diet of the subject was berry free for the duration of the intervention, but was not otherwise controlled for other food high in antioxidants and polyphenols. Vitamin C content was lower on the Pbo treatment compared to intervention treatment.  Power calculation: Not stated.  Source of funding: Funded by the California Strawberry Commission.  Site of recruitment: Sacremento, California, community and surrounding region were recruited using newspaper and online advertisements and local flyers (p. 47).  Adherence/compliance: "During the two 6-week feeding periods, subjects returned to the testing center at biweekly intervals to pick up the Str or	Method of measuring adherence and addressing in changes in diet reduces the risk of bias.  However without a washout period, not controlling for physical activity lower vitamin c (antioxidant) content in placebo and funding from industry, this study puts this study at high risk of bias.
Overall risk of bias		Unclear risk of bias secondary to unmasked investigators and no method to reduce potential
5 . J. 11 11 11 11 11 11 11 11 11 11 11 11 11		carry over effects.

The Cochrane Collaboration's Tool for Assessing Risk of Bias		Study Design: Single-Centre, Randomised, Single Blinded, Placebo-Controlled Cross-over Trial	
	Cappozzo, J.; Sandhya, K.; Ellis, C.L.; Tadapaneni,		
	n postprandial inflammation and insulin. Br. J. Nut	r. <b>2011</b> , 106, 913–922.	
Domain	Support for judgment	Review authors' judgment	
Selection bias			
Random sequence generation	"During the experiment, the subjects consumed two test meals in random order, with each subject serving as his/her own control. (p. 914)".	Unclear risk of bias as method of randomization not reported.	
Allocation concealment	Not stated.	Unclear risk of bias as allocation concealment not reported	
Performance bias			
Blinding of participants and personnel (Assessments should be made for each main outcome or class of outcomes)	States it was single-blinded.	Suggests that participants were masked but method of masking was not reported Treatment both matched of volume, favour, and nut contribution.  Low risk of bias	
Detection bias			
Blinding outcome assessment (Assessments should be made for each main outcome or class of outcomes)	Not stated.	Investigators not blinded but outcomes are objective measures and the cross over design reduces the risk of detection affecting the results.  Low risk of bias	
Attrition bias			
Incomplete outcome data (Assessments should be made for each main outcome or class of outcomes)	"Of the sixteen women, two dropped out of the study because of work commitments. (p. 914)".	No intention to treat analysis and not stated at which stage did the participants drop out but cross over design so Low risk of bias	
Reporting bias			
Selective reporting	Baseline inflammatory markers not reported (p. 919). Only looked at between group differences.	Unclear risk of bias Low risk of bias	
Other bias			

Other sources of bias	Carry over effect: "Briefly, the subject reported to the laboratory in the morning in a fasting state on two occasions 3–5 days apart (p. 914)."  Confounding: "Eligible subjects had a 7 day run-in before the actual experiment during which they were required to avoid consuming berries, including strawberries, while mainting all other aspects of their diet and physical activity. (p. 914)."  Power calculation: Not stated.  Source of funding: Funded by strawberry commission.  Site of recruitment: Sacramento, CA, USA	ıs
	commission.  Site of recruitment: Sacramento, CA, USA	
	community.  Adherence/compliance: N/A as on one occasion	
Overall risk of bias	Unclear risk of bia	as

The Cochrane Collaboration's Tool for assessing risk of bias		Study Design: Randomised, Cross over Design	
Study Details: Rankin, J. W.; Andreae, M.C.; Ch Diabetes Obes. Metab. 2008, 10, 1086–1096.	nen, C.Y.O.; O'Keefe, S.F. E	ffect of raisin consumption or	n oxidative stress and inflammation in obesity.
Domain	Support for judgmen	t	Review authors' judgment
Selection bias			
Random sequence generation	design was used in ord	l, counterbalanced, cross ler to have subjects undergo lacebo treatments (p. 1087)."	Unclear risk of bias as method of randomization not reported
Allocation concealment	Not stated		Unclear risk of bias as allocation concealment not reported
Performance bias			
Blinding of participants and personnel (Assessments should be made for each main outcome or class of outcomes)	Not stated		Blinding not used due to the nature of the intervention, intervention = raisins, placebo = jelly candies. All participants were exposed to both treatments due to cross over design and therefore it is unlikely that lack of blinding would have influenced the results but Unclear risk of bias
Detection bias			
Blinding outcome assessment (Assessments should be made for each main outcome or class of outcomes)	Not stated		Lack of blinding is not likely to have influenced the outcome measurements, as these were objective (biomarkers of oxidative stress, inflammation and endothelial activation).  Low risk of bias
Attrition bias			
Incomplete outcome data (Assessments should be made for each main outcome or class of outcomes)	"One of the original subjects dropped out because of personal reasons, while two were asked to discontinue participant because of a self-report of non-compliance to study requirements (p. 1089)."		Unclear risk of bias as it's not stated if these participants were or were not included in the analysis.
Reporting bias		· · · · · · · · · · · · · · · · · · ·	
Selective reporting	Outcomes as per methods Oxidative stress	Reported in results (Yes/No) Yes (p. 1091)	Low risk of bias as reported on all outcomes  — measured

	Inflammation Yes (p. 1091)	
Other bias		
Other bias  Other sources of bias	Carry over effect: "14 days of washout between interventions (p. 1087)"  Confounding: "Subjects were asked to maintain their weight and physical activity level as well as refrain from taking any dietary supplements or anti-inflammatory medications 2 weeks prior to and for the duration of the study." "During the controlled feeding period of each intervention, subjects were provided with all their food. (p. 1087)."  Power calculation: Not stated  Source of funding: California Raisin Marketing Board (p. 1095).	Unclear risk of bias as accounted for carry over effect and confounding but method of assessing adherence to diet is flawed as it relies on participants to recall their adherence and the study is industrially funded.
	Site of recruitment: Not stated	_
	Adherence/compliance: Assessed by self-reported	_
	exit survey	
Overall risk of bias		Unclear risk of bias

The Cochrane Collaboration's Tool for Assessing Risk of Bias		Study Design: Double-Blind, Randomized Cross over Trial	
<b>Study Details:</b> Auclair, S.; et al. The regular consumption of a polyphenol-rich apple does not influence endothelial function: A randomised double-blind trial in hypercholesterolemic adults <i>Eur. J. Clin. Nutr.</i> <b>2010</b> , <i>64</i> , 1158–1165.			
Domain	Support for judgment	Review authors' judgment	
Selection bias		, ,	
Random sequence generation	"double-blind, randomized crossover trial"	Unclear risk of bias as method of randomization not reported	
Allocation concealment	Not stated	Unclear risk of bias as allocation concealment not reported	
Performance bias			
Blinding of participants and personnel (Assessments should be made for each main outcome or class of outcomes)	The study design was a double-blinded crossover. (p. 1159). The investigators were blinded with regard to the nature of the apple samples, as were the participants, This was ensured by balancing the samples for simple sugars and dietary fibres, creating homogenous samples (with exception of course to the polyphenol content)	Low risk of bias	
Detection bias	,		
Blinding outcome assessment (Assessments should be made for each main outcome or class of outcomes)  Attrition bias	"Investigators were blinded with regard to the nature of the apple sample. The study design was a double-blinded crossover." (p. 1159).	Low risk of bias	
Incomplete outcome data (Assessments should be made for each main outcome or class of outcomes)	"A total of 30 hypercholesterolemic men were included in the study (p. 1159)". Results section reports on baseline characteristics of 30 volunteers (p. 1160). Insufficient reporting of dropouts and no mention of missing data.	Low risk of bias as this suggests that all participants completed the study was included in analysis.	
Reporting bias			
Selective reporting	Reported on FMD and biochemical parameters as per methods (p. 1162).	Low risk of bias as all outcomes were reported	
Other bias			
Other sources of bias	Carry over effect: "4 week washout period" (p. 1158)	Low risk of bias due to method of reducing carry	

	Confounding: "maintained their usual diet during	over effect, bias due to non-compliance and
	the whole study (p. 1160)."	confounding from diet.
	Power calculation: Not done	
	Source of funding: "This work was supported by	<del>-</del>
	the European Community (p. 1163)."	
	Site of recruitment: Not stated.	_
	Adherence/compliance: "Unused bags were	_
	returned at the following visit and were counted to	
	check for compliance (pp. 1159–1160)."	
	"Compliance was assessed by measuring phloretin	
	excretion in urine (p. 1160)"	
Overall risk of bias		Low risk of bias

### The Cochrane Collaboration's Tool for Assessing Risk of Bias

Study Design: Randomised, Double-Blind, Placebo-Controlled Trial

**Study Details:** Wright, O.R.; Netzel, G.A.; Sakzewski, A.R. A randomized, double-blind, placebo-controlled trial of the effect of dried purple carrot on body mass, lipids, blood pressure, body composition, and inflammatory markers in overweight and obese adults: the QUENCH trial. *Can. J. Physiol. Pharmacol.* **2013**, *91*, 480–488.

Domain	Support for judgment	Review authors' judgment
Selection bias		
Random sequence generation	States it's a randomised, double blind, placebo-controlled trial.	Unclear risk of bias as method of randomization not reported
Allocation concealment	Not stated	Unclear risk of bias as allocation concealment not reported
Performance bias		
Blinding of participants and	"All participants and study investigators were blinded to whether	
personnel	participants were consuming the intervention or the placebo throughout	Low risk of bias
(Assessments should be made for each	the trial (p. 481)" "The control was dried orange carrot. 'It was coloured	LOW TISK OF DIAS
main outcome or class of outcomes)	purple using natural purple colouring. (p. 481)"	
Detection bias		
Blinding outcome assessment	States its double blinded "All participants and study investigators were	
(Assessments should be made for each	blinded to whether participants were consuming the intervention or the	Low risk of bias
main outcome or class of outcomes)	placebo throughout the trial (p. 481)"	
Attrition bias		
Incomplete outcome data	"one not completing for unknown reasons. This participant was	I are rick of high an all participants
(Assessments should be made for each	included in the final analysis, in line with the intention-to-treat analysis."	Low risk of bias as all participants were accounted for
main outcome or class of outcomes)	included in the inial analysis, in line with the intention-to-treat analysis.	were accounted for
Reporting bias		
Selective reporting	All outcomes measured were reported as evidenced by table and results section on p. 483.	Low risk of bias
Other bias		
Other sources of bias	Carry over effect: N/A as parallel design	Low risk of bias but likely that the

Confounding: "Potential participants were excluded if they were already consuming purple carrots or purple carrot products (p. 481)." "The study was restricted to males to minimize confounding due to gender. Males and females are known to differ systematically for 2 of the key outcome measures of the trial: inflammatory state and body composition. Females experience regular fluctuations in hormones that influence inflammatory state, and generally have a higher proportion of body fat than males. (p. 481)." "Participants were requested to maintain their usual dietary and physical activity habits for the duration of the study. (p. 481)" "Participants completed the Wollongong Dietary Inventory to measure dietary intake at baseline and 4 weeks. Asked for brief description of the amount of time spent in intentional physical activity per week to qualitatively monitor whether this changed during the trial (p. 482)."

study is underpowered to see a significant effect

Power calculation: No stated

Source of funding: University of Queensland's Early Career Researcher Fund. Summer Scholarship Program. Industry funding

Site of recruitment: 'Email advertisements posted by the Wesley Research Institute, Brisbane, Queensland, University of Queensland, and through a commercial television program were screened via telephone. (p. 481)"

Adherence/compliance: "Participants completed an intervention intake form for each day of the trial. This was cross-checked against the empty sachet packets returned at follow-up (p. 482)."

Overall risk of bias Low risk of bias

The Cochrane Collaboration's Tool for Assessing Risk of Bias		Study Design: Randomised Single-Blind Placebo Controlled Parallel Design	
<b>Study Details:</b> De Maat, M.P.; Pijl, H.; Kluft, C.; Princen, H.M. Consumption of black and green tea had no effect on inflammation, haemostasis and endothelial markers in smoking healthy individuals. <i>Eur. J. Clin. Nutr.</i> <b>2000</b> , <i>54</i> , 757–763.			
Domain	Support for judgment	Review authors' judgment	
Selection bias			
Random sequence generation	"Randomised study (p. 757)"	Unclear risk of bias as method of randomization not reported	
Allocation concealment	Not stated	Unclear risk of bias as allocation concealment not stated	
Performance bias			
Blinding of participants and personnel (Assessments should be made for each main outcome or class of outcomes)	States single-blinded but also states "control beverage was mineral water (p. 758)"	Unclear risk of bias it suggests that participants were masked but did not state method of providing mineral water appear and taste similar to intervention	
Detection bias			
Blinding outcome assessment (Assessments should be made for each main outcome or class of outcomes)	Not stated	Low risk of bias due to objective outcomes. Study investigators are presumed to have been blinded to treatment group however it is not cleat how this was achieved.	
Attrition bias			
Incomplete outcome data (Assessments should be made for each main outcome or class of outcomes)	"Five subjects did not complete the study (three dropped out during the run-in period and two dropped out during the intervention period), all because of social circumstances (p. 758)." results table states "for all subject" (p. 760).	Unclear risk of bias as statement in results table suggests an intention to treat analysis was performed but no mention that ITT analysis performed in text.	
Reporting bias			
Selective reporting	All outcomes measured were reported in table on p. 760.	Low risk of bias	
Other bias			
Other sources of bias	Carry over effect: "During a run-in period of 2 weeks the subjects drank six cups (50 mL) of the control beverage (mineral water) daily (p. 758)."	Low risk of bias	

110000000000000000000000000000000000000		020 01 010
	Confounding: "The subjects were instructed by a	
	dietitian to adhere to their normal eating habits	
	during the intervention as closely as possible. (p. 758)"	
	Power calculation: Not stated	
	Source of funding: Unilever Research, Vaardingen,	
	The Netherlands (p. 761)	
	Site of recruitment: "Recruited through	
	advertisements in local newspapers and in Leiden	
	University Medical Centre for participation in the	
	study (p. 758)."	
	Adherence/compliance: "The subjects were asked to	
	stick the labels of their bags of tea or capsule boxes	
	in a daily diary as a compliance check (p. 758)."	
Overall risk of bias	Unclear risk of bia	ıs

The Cochrane Collaboration's Tool for Assessing Risk of Bias		Study Design: A Phase II Randomised Controlled Tea Intervention Parallel Trial		
Study Details: Hakim, I.A.; Harris, R.B.; Brown, S.; Chow, H.H.; Wiseman, S.; Agarwal, S.; Talbot, W. Effect of increased tea consumption on oxidative				
DNA damage among smokers: a randomized co	ontrolled study. <i>J. Nutr.</i> <b>2003</b> , <i>133</i> , 3303s–3309s.			
Domain	Support for judgment	Review authors' judgment		
Selection bias				
Random sequence generation	"Each individual was randomly assigned to drink 4 cups/d of decaffeinated green tea, decaffeinated black tea or water (p. 3304S). 'Once subjects met eligibility criteria and successfully passed the 1-mo run-in period, randomization occurred using a random-permuted block design (block size = 6). Randomization lists were prepared prior to beginning the study, with schedules separate for men and women (p. 3305S)."	Low risk of bias as method of random number generation performed		
Allocation concealment	No stated	Unclear risk of bias as allocation concealment not reported		
Performance bias				
Blinding of participants and personnel (Assessments should be made for each main outcome or class of outcomes)	"Because this was a study comparing the use and consumption of real foodstuffs, it was impossible to blind the intervention to either staff or subjects (p. 3304S)." Blinding of participants and investigators was not possible due to the nature of the intervention (green tea vs. black tea vs. water). Adherence to the intervention was high (95% across all groups), however consumption was higher than required in the green tea group making it likely that knowledge of treatment influenced subjects behaviours and could have influenced results.	High risk of bias due to unmasking participants and investigators from intervention products		
Detection bias				

Blinding outcome assessment (Assessments should be made for each main outcome or class of outcomes)	"Urinary 8-OHdG: Baseline through 4-mo samples from the same individual were batched for analysis with the laboratory blinded to treatment status (p. 3305S)"	Low risk of bias
Attrition bias	•	
Incomplete outcome data (Assessments should be made for each main outcome or class of outcomes)	"143 heavy smoker recruited (p. 3304S)'. '33 men and 100 women completed the trial and were included in this analysis." 143 subjects were randomised and 133 completed the intervention. Reasons for dropout were (1) moving out of the area and (2) not having enough time. Intention-to-treat analysis was not employed however the reasons for dropout are not related to the intervention and unlikely to influence the results	Suggests no intention to treat analysis, unclear if there would be a difference due to the small number of participants excluded. Unclear risk of bias
Reporting bias		
Selective reporting	Reported on outcomes measured as per results section but only change from baseline and change between groups reported. No baseline and final data reported.	Low risk of bias
Other bias		
	Carry over effect: N/A as parallel design Confounding: Adjusted for confounding in statistical analysis.	
Other sources of bias	Power calculation: "A sample size of 135 individuals was estimated to provide statistical power of 80% to detect a 20% reduction in urinary excretion of 8-OHdG by either green or black tea compared with the control (water) group (p. 3306S)."  Source of funding: Not stated.	Low risk of bias
	Site of recruitment: Tucson, Arizona.	

Adherence/compliance: "Primary adherence to the study intervention was evaluated by self-reporting via monthly intake calenders.

Completed 4 24 h diet assessment of maintainance of overall food intake. Short smoking questionnaire. Self-report measures of study protocol adherence and tea consumption.

Measured urinary and plasma catechin levels at monthly visits (p. 3305S)."

Side effect monitoring: "They were telephoned during the week before each follow up visit to confirm the date and time of the next appointment and to identify any problems or side effects associated with study participation. (p. 3305S)."

Overall risk of bias

Low risk of bias

The Cochrane Collaboration's Tool for assessing risk of bias		Study Design: 3 Arm Randomised Cross-over Trial	
<u>-</u>		•	rine polyphenols, in the absence of alcohol, reduce
lipid peroxidative stress in smoking subjects. Fr			
Domain	Support for judgment	t	Review authors' judgment
Selection bias			
Random sequence generation	"In this study using La volunteers were rando (p. 637)."	atin Square design, omly allocated to drink either.	Low risk of bias as random sequence generation technique used
Allocation concealment	Not stated		Unclear risk of bias due to allocation concealment not reported
Performance bias			
Blinding of participants and personnel (Assessments should be made for each main outcome or class of outcomes)	Not stated. Blinding was not used in this study. Although biomarkers for compliance with alcohol consumption were measured.		Unclear risk of bias
Detection bias	•		
Blinding outcome assessment (Assessments should be made for each main outcome or class of outcomes)	Not stated.  Blinding was not used, however all outcome measures are objective making it unlikely that lack of blinding could have influenced the results.		Low risk of bias
Attrition bias			
Incomplete outcome data (Assessments should be made for each main outcome or class of outcomes)	Data reported for dealcoholised red wine group state " $n = 17$ " while other groups state " $n = 18$ ".		Unclear risk of bias as this suggests that not all data was included or values were included in analysis or that one participant did not finish all 3 intervention periods but was included in analysis.
Reporting bias			•
, ,	Outcomes as per methods	Reported in results (Yes/No)	- Low risk of bias
Selective reporting	Oxidative stress	Yes (p. 639)	LOW TISK OF DIAS
	Plasma vitamins	Yes (p. 640)	
Other bias			

, ,		
Other sources of bias	Carry over effect: "a 1 week washout at the start of the study and between each beverage (p. 637)."  Confounding: "Asked to maintain smoking habits throughout the study. Subjects were instructed to always smoke the same number of cigarettes and at the same time prior to each laboratory visit. They were also asked to avoid any antioxidant supplements or over-the-counter medication and not to consume any other alcoholic beverages other than those provided (p. 637)."  Power calculation: Not reported  Source of funding: "Supported by the Australian Grape Wine Research and Development  Corporation and the Medical Research Foundation of Royal Perth Hospital (p. 641)."  Site of recruitment: "Were recruited by	Unclear risk of bias Carry over effect is unlikely as the investigators confirmed a 24 h return to baseline of F2- isoprostanes after alcohol consumption, meaning the 7 day washout period was sufficient.
	1 1	_
	Adherence/compliance	
Overall risk of bias		Unclear risk of bias

The Cochrane Collaboration's Tool for Assess	Study Design: Double-Blind, Randomised, Cross over Dietary Intervention Study	
	indez, R.; Miranda, M.L.; Costa, A.F.; Jimenez-Jimenez, L.; Vallejo-Vaz and improve endothelial function in young women with mild hyperte	
Domain	Support for judgment	Review authors' judgment
Selection bias		
Random sequence generation	"For randomization, we used a random number generation method."	Low risk of bias due to method used
Allocation concealment	Not stated	Unclear risk of bias as allocation concealment not reported
Performance bias		
Blinding of participants and personnel (Assessments should be made for each main outcome or class of outcomes)	"Despite the investigators were aware of which diet the participants received, we do not rule out the possibility that a participant could recognize the taste of virgin olive oil (p. 1300)." States double blind study (p. 1300)	Unclear risk of bias
Detection bias	, , , , , , , , , , , , , , , , , , , ,	
Blinding outcome assessment (Assessments should be made for each main outcome or class of outcomes)	Same as above	Low risk of bias
Attrition bias		
Incomplete outcome data (Assessments should be made for each main outcome or class of outcomes)	"Six women refused to do so, and ten more abandoned after the first dietary intervention because of protocol violation (6), intolerance to the oils (3), or change of address (1). There were 24 women completed the study. (p. 1300)." 10 more abandoned after the study. Outcome data in table states " $n = 24$ " (p. 1301)	Intention- to-treat analysis may have provided indication of whether or not doing it would have affected the results. However due to cross-over design, if ITT analysis was performed it may have biased results.  Unclear risk of bias
Reporting bias		
Selective reporting	Outcomes as per Reported in results (Yes/No)	_ Low risk of bias
	BP Yes (p. 1301)	

Healthcare <b>2016</b> , 4, 69				S33 of S40
	Endothelial function	Yes (p. 1301)		
	Oxidative stress	Yes (p. 1301)		
	Inflammation	Yes (p. 1301)		
Other bias				
	Carry over effect: "Run	inn period of 4 months (p. 1299)." "4-		
	week washout between	diets (p. 1299)."	_	
	Confounding: "main	tain their usual levels of exercise for the		
	duration of the study (p	o. 1300)." "same calories as habitual diet		
	(p. 1300)"		_	
	Power calculation: Not	done		
Other sources of bias	Source of funding: "CIT	OLIVA Foundation, Instituto de Salud	Low risk of bias	
	Carlos III and Juta de A	ndalucia grants (p. 1303)."	_	
	Site of recruitment: "We consecutively asked to enter the study			
	to forty Caucasian women that were newly diagnosed with			
	high-normal BP or stage 1 essential hypertension (p. 1300)."		_	
	Adherence/compliance	"The duration of this period was to	_	
	ensure adequate experi	ence in protocol adherence (p. 1300)."		
Overall risk of bias			Low risk of bias	

The Cochrane Collaboration's Tool for A	ssessing Risk of Bias	Study Design: Randomised Cross-over Trial
Study Details: Ruano, J.; Lopez-Miranda, J.; Fuentes, F.; Moreno, J.A.; Bellido, C.; Perez-Martinez, P.; Lozano, A.; Gómez, P.; Jiménez, Y.; Jiménez, F.P. Phenolic		
content of virgin olive oil improves ischen	nic reactive hyperemia in hypercholesterolemic patients. J. Am. Coll. C	Cardiol. <b>2005</b> , 46, 1864–1868.
Domain	Support for judgment	Review authors' judgment
Selection bias		
Random sequence generation	"randomised sequential crossover design. (p. 1864)"	Unclear risk of bias as method not reported
Allocation concealment	Comment: Not stated	Unclear risk of bias as not reported
Performance bias		
Blinding of participants and personnel		Suggests that participants were not masked
(Assessments should be made for each	Comment: Not stated	High risk of bias
main outcome or class of outcomes)		Unclear risk of bias
Detection bias		
Blinding outcome assessment		Suggests that investigators were not masked
(Assessments should be made for each	Comment: Not stated	High risk of bias
main outcome or class of outcomes)		Low risk of bias due to objective measures
Attrition bias		
Incomplete outcome data		Suggests that all participants were included in
(Assessments should be made for each	Comment: No dropouts stated.	the analysis but unclear risk of bias
main outcome or class of outcomes)		the analysis but unclear risk of blas
Reporting bias		
	Comment: All outcomes measured were reported. **Basal lipid	
Selective reporting	parameters were not shown but are not found to be significantly	Low risk of bias
	differently between participants in either group.	
Other bias		
	Carry over effect: No washout period stated.	_
	Confounding: Not stated .No dietary assessment done.	_
	Power calculation: Not stated	_
Other sources of bias	Source of funding: Not stated	- High risk of bias as design do not account for
	Site of recruitment: "from the Lipids and Stheroscleosis Unit at	carry over effect.
	Hospital Univeritario Reina Sofia (Cordoba, Spain) participated	carry over effect.
	in the study (p. 1864)."	_
	Adherence/compliance: N/A as administered once by	
	investigator	
Overall risk of bias		Unclear risk of bias

The Cochrane Collaboration's Tool for Assessing Risk of Bias		Study Design: Double-Blind Randomised Trial	
5	mmer, A.J.; Sexton, J.; Lennon, R.; Romani, A.; Mulinacci, N		
Beneficial effects of polyphenol-rich olive oil in	patients with early atherosclerosis. Eur. J. Nutr. 2013, 52, 1	223–1231.	
Domain	Support for judgment	Review authors' judgment	
Selection bias			
Random sequence generation	Participants were then randomised to receive a once daily serving of 30ml of either EGCG containing OO or OO alone for a total duration of four months (p. 3)	Unclear risk of bias as method of randomization not reported	
Allocation concealment	Not stated	Unclear risk of bias as allocation concealment not reported	
Performance bias			
Blinding of participants and personnel (Assessments should be made for each main outcome or class of outcomes)	States it's a double blinded study	Unclear risk of bias method of masking was not reported and thus cannot determine if masking can be broken	
Detection bias			
Blinding outcome assessment (Assessments should be made for each main outcome or class of outcomes)	States it's a double blinded study	Unclear risk of bias method of masking was not reported and thus cannot determine if masking can be broken. Low risk of bias as objective measures	
Attrition bias			
Incomplete outcome data (Assessments should be made for each main outcome or class of outcomes)	"Statistical analysis was performed by an independent statistician blinded to the randomization after completion of the studies. (p. 4)"	Tables suggest intention to treat analysis done as not all have $n = 52$ , however dropouts also not stated. Suggests unclear risk of bias.	
Reporting bias			
Selective reporting	Outcomes for within group OO-ECG for inflammatory markers not reported.	Unclear risk of bias	
Other bias			
Other sources of bias	Carry over effect: N/A due to parallel study design.	Low risk of bias	

Side effects: "Participants were also contacted by phone at one and three months to assess compliance and any changes in medications or symptoms (p. 3)."

Confounding: "Participants were instructed to not change their diets despite olive oil supplementation, and were not given any special dietary instruction so as to have olive oil as the sole added variable in their diet (p. 3)."

Power calculation: Not stated

Source of funding: This was partly supported by
Olivi Agri Team Srl-Groseeto, Italy and the
University of Florence. However, the study was investigator initiated and investigator driven (p. 7).

Site of recruitment: 'Patients recruited from the
Division of Cardiovascular Diseases at Mayo Clinic in Rochester, MN as well as by intra-institutional advertising seeking research participants. (p. 2)

Adherence/compliance: As above

Overall risk of bias

Unclear risk of bias

The Cochrane Collaboration's Tool for Assessing Risk of Bias		Study Design: Randomised Controlled Double-Blind Cross over Study	
<b>Study Details:</b> Clerici, C.; Nardi, E.; Battezzati, P.M.; Asciutti, S.; Castellani, D.; Corazzi, N.; Giuliano, V.; Gizzi, S.; Perriello, G.; Matteo, G.; Galli, Setchell, K.D. Novel soy germ pasta improves endothelial function, blood pressure, and oxidative stress in patients with type 2 diabetes. <i>Diabetes</i> <b>2011</b> , <i>34</i> , 1946–1948.			
Domain	Support for judgment	Review authors' judgment	
Selection bias	, ,	, 0	
Random sequence generation	"Patients were randomised to two groups. (p. 1946)."	Unclear risk of bias as method of randomization not reported	
Allocation concealment	Not stated	Unclear risk of bias as allocation concealment not reported	
Performance bias			
Blinding of participants and personnel (Assessments should be made for each main outcome or class of outcomes)	"(Pasta +) and conventional pasta (Pasta-), with both packaged identically. (p. 1946)."	Suggests low risk of bias due to identical presentation. Taste may differ though	
Detection bias			
Blinding outcome assessment (Assessments should be made for each main outcome or class of outcomes)	States "double blinded"	Unclear risk of bias as method outcomes blinded to and method were not stated Low risk of bias	
Attrition bias			
Incomplete outcome data (Assessments should be made for each main outcome or class of outcomes)	"Of the 26 patients enrolled, 6 were withdrawn (4 whose drug therapies were altered, 1 who took antioxidants, and 1 who was noncompliant to the diets) (pp. 1946–194–)." As evidenced by Supplementary Table 1: " $n = 20$ " for oxidized LDL, 8-iso-PGF2 $\alpha$ , GSH and IL-6, "only data concerning Period 1 were considered due to presence of sequence effect."	Low risk of bias Unclear risk of bias due to reason why noncompliant participant wasn't included in analysis due to cross over design	
Reporting bias			
Selective reporting	All outcomes measured were reported	Low risk of bias	
Other bias			
Other sources of bias	Carry over effect: "within a 4 week washout between (p. 1946)."	Unclear risk of bias	

	Confounding: Not stated	Effect seen was smaller than anticipated in
	Power calculation: Need at least 20 subjects to observe an improvement in serum total cholesterol of about 18 mg/dL with SD = 31 mg/dL when administered enriched pasta compared	power calculation suggesting risk of type 1 error is at 0.025 and study to have inadequate power.
	with conventional pasta (Supplementary Data).	
	Source of funding: Not stated	_
	Site of recruitment: Not stated.	
	Adherence/compliance: Not stated	
Overall risk of bias		Unclear risk of bias

The Cochrane Collab	poration's Tool for Assessing Risk of Bias	Study Design: Randomisted Controlled Parallel-Design Trial			
Study Details: Yang, X.; et al. The effects of a lupin-enriched diet on oxidative stress and factors influencing vascular function in overweight subjects.					
	Antioxid. Redox Signal. <b>2010</b> , 13, 1517–1524.				
Domain	Support for judgment	Review authors' judgment			
Selection bias					
Random sequence	"Randomisation was performed using computer-generated random	Low risk of bias			
generation	numbers concealed in opaque envelopes (p. 1518)"				
Allocation	Not stated asked as a second a				
concealment	Not stated whether envelopes were sealed or not.	Unclear risk of bias			
Performance bias					
Blinding of					
participants and	Not stated.	Unclear risk of bias			
personnel	- 10 0 0 11110 111				
(Assessments	Blinding is not utilised in this study. IT is unclear whther				
should be made for	participants knew of their treatment allocation or whether there				
each main outcome	were detectable differences in terms of appearance and taste of the				
or class of	two treatments.				
outcomes)					
Detection bias					
Blinding outcome					
assessment					
(Assessments	Not stated				
should be made for	Lack of blinding would be unlikely to influence the results due to	Low risk of bias			
each main outcome	the objective nature of all outcome measures.				
or class of					
outcomes)					
Attrition bias					

Incomplete outcome data (Assessments should be made for each main outcome or class of outcomes)	Comment: no intention to treat analysis but groups in similar. 88 participants initially randomised, 14 withdrew (8due to inability to eat required amount of bread, 4 due to time restraints, 1 due to moving interstate, 1 due to change in medication). The number of dropouts appears to be even across both groups ( $n = 37$ for both intervention and control groups), although the reasons for dropout may not have been similar for both treatment groups. All data for the 74 completing participants has been included.		Unclear risk of bias
Reporting bias			
Selective reporting	Outcomes as per methods	Reported in results (Yes/No)	- Low risk of bias
	Vascular function	Yes (p. 1521)	
	Oxidative stress	Yes (p. 1521)	
Other bias			
Other sources of bias	Carry over effect: N/A  Confounding: "Both groups required to replace approximately 15%–20% of their usual daily energy intake with bread. (p. 1518)" "Apart from this small shift in dietary intake, participants maintained their usual diet, physical activity, and medication regimen throughout the trial. (p. 1518)"  Power calculation: Based on 40 participants per group, the study was powered at 80% to detect a 25% difference in plasma and urinary  F2-isoprostanes and a 40% difference in plasma nitrite concentrations  (p. 1519). Under.  Source of funding: Western Australia Government (p. 1522)  Site of recruitment: Not stated  Adherence/compliance: "Compliance with the bread intake was assessed using a daily bread intake record where participants recorded the number of slices consumed each day throughout the		Risk of type 2 error due as underpowered due to inadequate sample size required to see change in outcome measures as predicted. Unclear risk of bias
Overall risk of bias	study (p. 1518)"		Unclear risk of bias